{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:14:28Z","timestamp":1786997668399,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.transci.2019.08.009","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T19:52:53Z","timestamp":1565207573000},"page":"590-595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A personalized approach to the management of VWD"],"prefix":"10.1016","volume":"58","author":[{"given":"Chai W.","family":"Phua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Berntorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2019.08.009_bib0005","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor","volume":"67","author":"Sadler","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.transci.2019.08.009_bib0010","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/S0021-9258(18)52225-0","article-title":"Von Willebrand factor mediates protection of FVIII from activated protein C-catalyzed inactivation","volume":"266","author":"Fay","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.transci.2019.08.009_bib0015","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-2516.2009.02025.x","article-title":"Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease","volume":"15","author":"Metjian","year":"2009","journal-title":"Haemophilia"},{"issue":"January (Suppl 1)","key":"10.1016\/j.transci.2019.08.009_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2007.01610.x","article-title":"The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007)","volume":"14","author":"Federici","year":"2008","journal-title":"Haemophilia"},{"issue":"March (12)","key":"10.1016\/j.transci.2019.08.009_bib0025","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2013-04-497123","article-title":"The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects","volume":"123","author":"Colucci","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transci.2019.08.009_bib0030","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","article-title":"Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)","volume":"1","author":"Kaufmann","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.transci.2019.08.009_bib0035","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/MBC.0000000000000158","article-title":"Desmopressin responsiveness at a capped dose of 15lg in type 1 von Willebrand disease and mild hemophilia A","volume":"25","author":"Siew","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1016\/j.transci.2019.08.009_bib0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2516.2011.02572.x","article-title":"DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII: C level and with haemophilic genotype","volume":"18","author":"Seary","year":"2012","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.transci.2019.08.009_bib0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2265.1993.tb00990.x","article-title":"Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers","volume":"38","author":"Fjellestad-Paulsen","year":"1993","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.1016\/j.transci.2019.08.009_bib0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","article-title":"Treatment of von Willebrand\u2019s disease","volume":"351","author":"Mannucci","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.transci.2019.08.009_bib0055","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1111\/hae.13452","article-title":"Desmopressin stimulation testing: response to intravenous and intranasal forms","volume":"24","author":"McCormick","year":"2018","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.transci.2019.08.009_bib0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.transci.2019.08.009_bib0065","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood.V74.6.1997.1997","article-title":"Consistency of responses to repeated DDAVP infusion in patients with von Willebrand\u2019s disease and hemophilia A","volume":"74","author":"Rodeghiero","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.08.009_bib0070","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD","volume":"111","author":"Castaman","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.transci.2019.08.009_bib0075","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"Federici","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.transci.2019.08.009_bib0080","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/00043426-200311000-00010","article-title":"Desmopressin (DDAVP) responsiveness in children with von Willebrand disease","volume":"25","author":"Revel-Vilk","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.transci.2019.08.009_bib0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0268-960X(91)90032-8","article-title":"Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease","volume":"5","author":"Rodeghiero","year":"1991","journal-title":"Blood Rev"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2019.08.009_bib0090","first-page":"5","article-title":"The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007)","volume":"14","author":"Federici","year":"2007","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2019.08.009_bib0095","first-page":"S41","article-title":"The use of DDAVP in children with bleeding disorders","volume":"60","author":"Ben-Ami","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.transci.2019.08.009_bib0100","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood-2017-05-786699","article-title":"Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels","volume":"130","author":"Lavin","year":"2017","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.transci.2019.08.009_bib0105","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V99.1.180","article-title":"Reduced von Willebrand factor survival in type Vicenza von Willebrand disease","volume":"99","author":"Casonato","year":"2002","journal-title":"Blood"},{"issue":"December (1)","key":"10.1016\/j.transci.2019.08.009_bib0110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/asheducation-2016.1.683","article-title":"New treatment approaches to von Willebrand disease","volume":"2016","author":"Lavin","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.transci.2019.08.009_bib0115","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM198310063091402","article-title":"Platelet aggregation induced by 1-desamino-8- D -arginine vasopressin (DDAVP) in type IIB von Willebrand\u2019s disease","volume":"309","author":"Holmberg","year":"1983","journal-title":"N Engl J Med"},{"issue":"February (7)","key":"10.1016\/j.transci.2019.08.009_bib0120","first-page":"701","article-title":"Von Willebrand\u2019s Disease","volume":"376","author":"Leebeek","year":"2017","journal-title":"N Engl J Med"},{"issue":"January (1)","key":"10.1016\/j.transci.2019.08.009_bib0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.12732","article-title":"Side effects of desmopressin in patients with bleeding disorders","volume":"22","author":"Stoof","year":"2016","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.transci.2019.08.009_bib0130","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/hae.12955","article-title":"Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey","volume":"22","author":"Windyga","year":"2016","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.transci.2019.08.009_bib0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.transci.2019.08.009_bib0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2516.2011.02573.x","article-title":"A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy","volume":"18","author":"Trigg","year":"2012","journal-title":"Haemophilia"},{"issue":"July (3)","key":"10.1016\/j.transci.2019.08.009_bib0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tmrv.2009.03.001","article-title":"Cryoprecipitate: the current state of knowledge","volume":"23","author":"Callum","year":"2009","journal-title":"Transfus Med Rev"},{"issue":"Suppl 3","key":"10.1016\/j.transci.2019.08.009_bib0150","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x","article-title":"Clinical management of patients with von Willebrand disease with a VHP vWF concentrate: the French experience","volume":"4","author":"Goudemand","year":"1998","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2019.08.009_bib0155","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transci.2019.08.009_bib0160","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH11-02-0057","article-title":"The pharmacokinetic diversity of two von Willebrand factor (VWF)\/factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study","volume":"106","author":"Kessler","year":"2011","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.transci.2019.08.009_bib0165","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1055\/s-0030-1255445","article-title":"Structure and function of a recombinant von willebrand factor drug candidate","volume":"36","author":"Turecek","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.transci.2019.08.009_bib0170","first-page":"262","article-title":"Towards personalised therapy for von Willebrand disease: a future role for recombinant products","volume":"14","author":"Favaloro","year":"2016","journal-title":"Blood Transfusion"},{"issue":"2","key":"10.1016\/j.transci.2019.08.009_bib0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MBC.0b013e3283254570","article-title":"Von Willebrand factor\/factor VIII concentrates in the treatment of von Willebrand disease","volume":"20","author":"Batlle","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"Suppl 2","key":"10.1016\/j.transci.2019.08.009_bib0180","first-page":"s33","article-title":"Surgical prophylaxis in Von Willebrand\u2019s Disease: a difficult balance to manage","volume":"6","author":"Franchini","year":"2008","journal-title":"Blood Transfus"},{"issue":"September (3)","key":"10.1016\/j.transci.2019.08.009_bib0185","article-title":"Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand\u2019s disease","volume":"88","author":"Makris","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2019.08.009_bib0190","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","article-title":"Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study","volume":"99","author":"Mannucci","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.transci.2019.08.009_bib0195","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"issue":"April (2)","key":"10.1016\/j.transci.2019.08.009_bib0200","first-page":"117","article-title":"Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy","volume":"7","author":"Mannucci","year":"2009","journal-title":"Blood Transfusion"},{"issue":"5","key":"10.1016\/j.transci.2019.08.009_bib0205","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1055\/s-0030-1255445","article-title":"Structure and function of a recombinant von Willebrand factor drug candidate","volume":"36","author":"Turecek","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2019.08.009_bib0210","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","article-title":"Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial","volume":"122","author":"Mannucci","year":"2013","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.transci.2019.08.009_bib0215","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jth.14313","article-title":"Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery","volume":"17","author":"Peyvandi","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.transci.2019.08.009_bib0220","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2012.02916.x","article-title":"Prophylaxis in severe forms of von Willebrand\u2019s disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)","volume":"19","author":"Abshire","year":"2013","journal-title":"Haemophilia"},{"issue":"June (4)","key":"10.1016\/j.transci.2019.08.009_bib0225","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MBC.0000000000000257","article-title":"Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network","volume":"26","author":"Holm","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9","key":"10.1016\/j.transci.2019.08.009_bib0230","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.12995","article-title":"Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand disease prophylaxis network","volume":"13","author":"Abshire","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"July (4)","key":"10.1016\/j.transci.2019.08.009_bib0235","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/hae.13473","article-title":"Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network","volume":"24","author":"Holm","year":"2018","journal-title":"Haemophilia"},{"issue":"February","key":"10.1016\/j.transci.2019.08.009_bib0240","first-page":"13","article-title":"New data from the Italian National Register of Congenital Coagulopathies, 2016 Annual Survey","author":"Abbonizio","year":"2019","journal-title":"Blood Transfus"},{"issue":"November (11)","key":"10.1016\/j.transci.2019.08.009_bib0245","article-title":"Von Willebrand Disease Prophylaxis Network Steering Committee. The von Willebrand disease prophylaxis network: exploring a treatment concept","volume":"4","author":"Berntorp","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"July (4)","key":"10.1016\/j.transci.2019.08.009_bib0250","first-page":"371","article-title":"Current challenges in the diagnosis and management of patients with inherited von Willebrand\u2019s disease in Italy: an Expert meeting Report on the diagnosis and surgical and secondary long-term prophylaxis","volume":"16","author":"Schinco","year":"2018","journal-title":"Blood Transfus"},{"issue":"May (Suppl 4)","key":"10.1016\/j.transci.2019.08.009_bib0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hae.13475","article-title":"Fifth \u00c5land Island conference on von Willebrand disease","volume":"24","author":"Berntorp","year":"2018","journal-title":"Haemophilia"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219301545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050219301545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:50:44Z","timestamp":1761468644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050219301545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1473050219301545"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2019.08.009","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A personalized approach to the management of VWD","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2019.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}